Bicycle Therapeutics plc (NASDAQ:BCYC) Shares Acquired by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC boosted its stake in shares of Bicycle Therapeutics plc (NASDAQ:BCYCFree Report) by 34.0% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 6,727 shares of the company’s stock after purchasing an additional 1,706 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Bicycle Therapeutics were worth $122,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Deutsche Bank AG grew its position in Bicycle Therapeutics by 1,051.4% during the third quarter. Deutsche Bank AG now owns 96,370 shares of the company’s stock worth $1,936,000 after buying an additional 88,000 shares during the period. Polar Capital Holdings Plc grew its position in Bicycle Therapeutics by 33.2% during the third quarter. Polar Capital Holdings Plc now owns 1,011,500 shares of the company’s stock worth $20,321,000 after buying an additional 252,000 shares during the period. Morgan Stanley grew its position in Bicycle Therapeutics by 12.7% during the third quarter. Morgan Stanley now owns 1,621,749 shares of the company’s stock worth $32,581,000 after buying an additional 182,182 shares during the period. The Manufacturers Life Insurance Company grew its position in Bicycle Therapeutics by 43.6% during the third quarter. The Manufacturers Life Insurance Company now owns 36,092 shares of the company’s stock worth $725,000 after buying an additional 10,956 shares during the period. Finally, RA Capital Management L.P. acquired a new position in Bicycle Therapeutics during the third quarter worth about $16,072,000. 86.15% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on BCYC shares. Canaccord Genuity Group reiterated a “buy” rating and issued a $60.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, February 21st. JMP Securities lowered their price target on shares of Bicycle Therapeutics from $44.00 to $32.00 and set a “market outperform” rating on the stock in a research report on Wednesday, December 20th. HC Wainwright lowered their price target on shares of Bicycle Therapeutics from $57.00 to $55.00 and set a “buy” rating on the stock in a research report on Wednesday, February 21st. Finally, Needham & Company LLC reissued a “buy” rating and set a $43.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday, February 21st. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, Bicycle Therapeutics has an average rating of “Moderate Buy” and an average target price of $47.88.

Check Out Our Latest Analysis on Bicycle Therapeutics

Bicycle Therapeutics Stock Performance

NASDAQ:BCYC opened at $25.49 on Friday. The company has a quick ratio of 8.08, a current ratio of 8.08 and a debt-to-equity ratio of 0.08. The company has a market cap of $765.72 million, a P/E ratio of -4.97 and a beta of 0.90. Bicycle Therapeutics plc has a fifty-two week low of $12.54 and a fifty-two week high of $28.91. The firm’s 50 day moving average is $21.47 and its two-hundred day moving average is $18.94.

Bicycle Therapeutics (NASDAQ:BCYCGet Free Report) last released its quarterly earnings data on Tuesday, February 20th. The company reported ($1.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.23) by $0.07. Bicycle Therapeutics had a negative net margin of 669.72% and a negative return on equity of 57.80%. The company had revenue of $5.33 million during the quarter, compared to analyst estimates of $11.68 million. Analysts expect that Bicycle Therapeutics plc will post -5.2 EPS for the current year.

Insider Transactions at Bicycle Therapeutics

In other news, CEO Kevin Lee sold 8,703 shares of the stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $17.50, for a total value of $152,302.50. Following the completion of the sale, the chief executive officer now owns 390,428 shares of the company’s stock, valued at $6,832,490. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, insider Nigel Crockett sold 2,643 shares of the firm’s stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $17.50, for a total transaction of $46,252.50. Following the completion of the sale, the insider now directly owns 48,716 shares of the company’s stock, valued at approximately $852,530. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Kevin Lee sold 8,703 shares of the firm’s stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $17.50, for a total transaction of $152,302.50. Following the sale, the chief executive officer now directly owns 390,428 shares of the company’s stock, valued at $6,832,490. The disclosure for this sale can be found here. Insiders sold 11,950 shares of company stock valued at $209,125 over the last 90 days. Corporate insiders own 10.20% of the company’s stock.

Bicycle Therapeutics Profile

(Free Report)

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II and phase II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.

Recommended Stories

Want to see what other hedge funds are holding BCYC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bicycle Therapeutics plc (NASDAQ:BCYCFree Report).

Institutional Ownership by Quarter for Bicycle Therapeutics (NASDAQ:BCYC)

Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.